Alterity Therapeutics Limited
PRNAF
$0.01
$0.00133.33%
OTC PK
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | 2.12% | 129.78% | |||
| Total Revenue | 2.12% | 129.78% | |||
| Cost of Revenue | 1.99% | -2.90% | |||
| Gross Profit | 2.11% | 135.26% | |||
| SG&A Expenses | 2.11% | -36.87% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | 2.08% | -47.83% | |||
| Total Operating Expenses | 2.12% | 15.24% | |||
| Operating Income | -2.12% | 9.14% | |||
| Income Before Tax | -2.12% | 34.16% | |||
| Income Tax Expenses | 2.35% | -- | |||
| Earnings from Continuing Operations | -2.11% | 33.24% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -2.11% | 33.24% | |||
| EBIT | -2.12% | 9.14% | |||
| EBITDA | -2.12% | 9.08% | |||
| EPS Basic | 0.00% | 50.00% | |||
| Normalized Basic EPS | 0.00% | 33.33% | |||
| EPS Diluted | 0.00% | 60.00% | |||
| Normalized Diluted EPS | 0.00% | 33.33% | |||
| Average Basic Shares Outstanding | 0.00% | 40.78% | |||
| Average Diluted Shares Outstanding | 0.00% | 40.78% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||